1 ex to determine clinical characteristics and
vital status.
2 contacted for symptoms, clinical events, and
vital status.
3 elated to trial phase, institution type, and
vital status.
4 psychotic depression but was not related to
vital status.
5 ormed to obtain baseline characteristics and
vital status.
6 ructosamine assays were performed blinded to
vital status.
7 er mobile phone to update information on her
vital status.
8 sing date of birth, diagnosis, or last known
vital status.
9 t screening histories, incident cancers, and
vital status.
10 tion to ascertain incident hip fractures and
vital status.
11 ational Death Index to ascertain their later
vital status.
12 until May 31, 2019, to obtain information on
vital status.
13 AIDS Programme database to ascertain ART and
vital status.
14 ology Score II), organ failure supports, and
vital status.
15 Of 497 (86%) with ascertained
vital status,
340 (69%) were alive and, in 278 (82%) cas
16 ed in all women who had at least one updated
vital status after baseline interview.
17 nd sex among guideline-eligible patients for
vital status (
alive/dead) at 24 months.
18 follow-up of 212733 surgical cases using VHA
Vital Status and admission records were obtained with 10
19 roughout the United States and combined with
vital status and cause of death data through December 31
20 Vital status and cause of death of all patients eligible
21 Vital status and cause of death was determined during 19
22 Information regarding
vital status and cause of death was obtained from the Na
23 Their
vital status and cause of death were ascertained by comp
24 Vital status and cause of death were ascertained for the
25 Vital status and cause of death were ascertained through
26 Vital status and cause of death were ascertained through
27 Vital status and cause of death were determined through
28 Vital status and cause of death were obtained from Natio
29 cluding initial SUD episode and any relapse,
vital status and cause of death, and professional conseq
30 an areas followed from 1982 through 2004 for
vital status and cause of death.
31 Vital status and causes of death were ascertained using
32 Vital status and date and cause of death were ascertaine
33 e and passive follow-up methods to determine
vital status and date of death for 1,954 pancreatic canc
34 Vital status and death date information was queried usin
35 We ascertained the
vital status and development of ESRD in 143 living kidne
36 s the demographics, health services use, and
vital status and discharge dispositions of patients with
37 ery were contacted by telephone to determine
vital status and functional capacity using the Duke Acti
38 ted symptom burden, ventilator outcomes, and
vital status and functional status at discharge and 3 an
39 Vital status and history of MI during follow-up were det
40 ons (2011-2013) with active surveillance for
vital status and hospitalizations.
41 We ascertained
vital status and identified predictors of mortality usin
42 Information on
vital status and infertility from the Danish Civil Regis
43 We ascertained the
vital status and lifetime risk of ESRD in 3698 kidney do
44 Vital status and medical history were ascertained from a
45 Vital status and MRS at the end of the trial were known
46 on surveys in these towns to collect data on
vital status and other characteristics of survey respond
47 Vital status and standardized mortality ratios (SMRs) we
48 is period, we surveyed the cohort to measure
vital status and subsequent TB episodes.
49 rhans'-cell histiocytosis to ascertain their
vital status and whether cancer had been diagnosed.
50 s calculated on the basis of length of stay,
vital status,
and 30-day readmissions.
51 Cancer recurrence,
vital status,
and cause of death were documented for a m
52 Cancer recurrence,
vital status,
and cause of death were documented for a m
53 s and emergency department visits, patients'
vital status,
and current antipsychotic drug status was
54 y and morphology, age and date at diagnosis,
vital status,
and date of death (if applicable) were col
55 diagnosis, morphology and topography, stage,
vital status,
and date of death or last contact) were in
56 logy Project through December 1994 to obtain
vital status,
and death certificates were obtained for t
57 ational or regional registries of cancer and
vital status,
and eligible cases were patients with brai
58 frequency matched to cases on year of birth,
vital status,
and maternal county of residence at delive
59 We determined treatments,
vital status,
and other factors using registry, intervie
60 all subjects to whom SSA assigned an unknown
vital status as well as all subjects whom SSA identified
61 Recently, during the
vital status ascertainment phase of an ongoing occupatio
62 protocol will enable researchers to maximize
vital status ascertainment while containing costs associ
63 mented by CLU vital status updates, improves
vital status assessment while increasing substantially t
64 Vital status at 1 year was available in 936 of 944 (99.2
65 days was sent a return postcard to ascertain
vital status at 1 year.
66 ospital charges for the index admission, and
vital status at 100 days.
67 Vital status at 24 months was known for 2960 (88.5%) pat
68 Vital status at 3 months was determined, and independent
69 ssion status based on clinical interview and
vital status at 5 years by using the National Death Inde
70 Loss to follow-up was low with
vital status at 6 months of age reported for 22,698 (98.
71 criterion standards of current work status;
vital status at 6 years; grip strength; walking velocity
72 Vital status at day 90 was available for 936 of 1117 (84
73 B from 2015 to 2019, including demographics,
vital status at diagnosis, treatment duration, treatment
74 f mechanical ventilation, and information on
vital status at hospital discharge was acquired.
75 Vital status at hospital discharge was the outcome measu
76 ristics were recorded as were procedures and
vital status at hospital discharge.
77 existing studies have not considered patient
vital status at ICU discharge.
78 Vital status at June 30, 1992, was obtained for the 1134
79 people without MS by sex, year of birth, age/
vital status at MS diagnosis, and region of residence (c
80 The outcome was
vital status at PICU discharge.
81 Vital status at study end was available for all patients
82 Based on patients' diagnostic codes and
vital status at the end of the admission, disease focus
83 time of SCU admission, at 24 hrs, as well as
vital status at the time of discharge from the SCU and h
84 Vital status,
cause of death and coronary heart disease
85 home visit about 60 days later to ascertain
vital status,
clinical outcome, and interval growth.
86 it was made about 60 days later to ascertain
vital status,
clinical outcome, and interval growth.
87 tion, 66 [11] years); long-term follow-up of
vital status,
conducted annually until 2005, ranged from
88 The
vital status could be updated on Dec 31, 2008, in all re
89 Additional
vital status data collection and subsequent analyses wer
90 hoc.Measurements and Main Results: We report
vital status data for 99.6% of the intention-to-treat po
91 The process uses the
vital status data service of the Social Security Adminis
92 A secondary analysis of recovered missing
vital status data was performed.
93 High-quality cancer and
vital status data, and continued progress in early diagn
94 With inclusion of recovered
vital status data, the excess relative mortality risk wa
95 therapy, following collection of additional
vital status data.Methods: Patients were randomized 2:2:
96 detectable CMV DNA at randomization, 437 had
vital-status data available through week 48 post-HCT at
97 VA and Medicare
vital-status data were used to calculate one-year surviv
98 Information on
vital status,
date of death and cause of death was obtai
99 Vital status,
date of death, and cause of death were obt
100 (2.9%) of 1440 (one individual did not have
vital status documented at 48 h) after randomisation (ad
101 21,390 HCC cases diagnosed with follow-up of
vital status during 1998-2008, there were 4,727 (22%) wi
102 efined by the Veterans Health Administration
vital status file.
103 ertained through corresponding inpatient and
vital status files, and risk-standardized rates were cal
104 rates were ascertained through corresponding
vital status files.
105 y and 1-year mortality were calculated using
Vital Status Files.
106 Vital status follow-up began with the date of exit from
107 Vital status follow-up was conducted via population regi
108 Vital status for 1,043 (97%) participants was ascertaine
109 We determined
vital status for 561 miners, and obtained a follow-up qu
110 The NDI and active follow-up agreed on
vital status for 91.2% of Hispanic EPESE subjects.
111 was followed for future cancer incidence and
vital status for a median of 7.0 years.
112 sive hemodynamic data, echocardiography, and
vital status for all patients referred for right heart c
113 invasive hemodynamics, echocardiography, and
vital status for all patients.
114 e National Death Index was used to ascertain
vital status for patients who could not be contacted.
115 A National Death Index search ascertained
vital status for those with incomplete follow-up.
116 edicaid Services claims data, we ascertained
vital status from date of surgery through December 31, 2
117 rom the National Danish Patient Registry and
vital status from the National Danish Civil Registration
118 gh only 34% of these differentiated LTFU for
vital status from withdrawal of consent.
119 Patient
vital status generally is passively obtained by cancer r
120 Vital status has been traced, and risk factors in adulth
121 Data collected included
vital status,
histologic findings, and therapeutic inter
122 ithm incorporating recency, maternal HIV and
vital status,
history of sexual activity, and age at dia
123 d clinical outcomes were obtained, including
vital status,
hypoxia, and lung transplant.
124 We report ART initiation and
vital status in children with HIV after 7 years of rollo
125 Vital status in September 2010 was obtained from the Med
126 Complete information about
vital status in the Ontario Cancer Registry was availabl
127 Vital status information at 10 years was complete for 84
128 Vital status information was available for all patients
129 Vital status information was queried using an institutio
130 occurrence of cholangiocarcinoma and obtain
vital status information.
131 n 1964 and 2013; 176 had valid follow-up and
vital status information.
132 in the original analysis owing to incomplete
vital status information.Objectives: Report ACM and impa
133 3 and 12 months post-discharge, we assessed
vital status,
instrumental activities of daily living, b
134 in 1999 to 2000, which included determining
vital status,
interviewing participants or proxies, and
135 Extended follow-up for
vital status is being conducted by sites or through cent
136 Complete and accurate ascertainment of
vital status is of great importance in cohort studies.
137 For stage I, data on all subjects for whom
vital status is unconfirmed should be sent to the SSA.
138 ed baseline and longitudinal data, including
vital status,
left ventricular ejection fraction (LVEF),
139 titution (2014-2015) were followed to obtain
vital status,
living location, and patient-reported outc
140 Depression status, cause of death, and
vital status might have been misclassified.
141 Two-year
vital status (
minimum, 688 days) was determined in 2375
142 e electronic health records were linked with
vital status obtained from the National Death Index.
143 randomization group, long-term follow-up of
vital status occurred between June and October 2024.
144 data were merged with BIRLS to determine the
vital status of 105,951 patients who underwent 8 types o
145 The
vital status of 12,373 people aged 65 y and over was det
146 The
vital status of 265 SLE patients and 355 controls enroll
147 In 2019, we verified information on the
vital status of 5983 participants (89%).
148 analytic techniques were used to compare the
vital status of 61 patients with psychotic major depress
149 compared clinical presentation, relapse, and
vital status of 78 patients with type 1 AIP who met the
150 We knew the
vital status of 93% of children (2,669/2,869) at 18 mont
151 Vital status of all participants was ascertained thirty-
152 The
vital status of each member of this cohort was ascertain
153 The
vital status of each patient was determined as of Decemb
154 h Index to obtain updated information on the
vital status of participants and to determine causes of
155 We determined the
vital status of patients over a median of 3.6 years (10%
156 tudy, which evaluated for up to 10 years the
vital status of patients who were originally enrolled in
157 The
vital status of study participants was ascertained throu
158 Vital status of study participants was ascertained throu
159 Vital status of the patients was determined through the
160 the maximum accuracy (78%) in predicting the
vital status of the patients.
161 The
vital status of the subjects was identified in October 1
162 Nine to 12 years later, the
vital status of these subjects was determined.
163 system (BIRLS) is a VA file that depicts the
vital status of U.S. veterans with 87% to 95% accuracy.
164 We recorded
vital status on June 1, 1999, and ascertained causes of
165 Patients with unknown or uninterpretable
vital status or graft survival time (n=264 [0.8%]) were
166 We incorporated the
vital status outcomes for these patients into analyses o
167 ariables to better predict patient outcomes:
vital status (
overall survival), metastasis (metastasis-
168 The working group defined 5 outcome domains:
vital status,
patient-reported outcomes, progression of
169 Vital status,
risk factor, and cause-of-death data, coll
170 n a cohort of over 200,000 employees, an SSA
vital status search reduced the size of the NDI death re
171 which respondents provided information about
vital status,
sociodemographic and socioeconomic charact
172 Patients were followed for
vital status through 180 days.
173 urvey in 1976 to 1980 and were monitored for
vital status through 1992 in the Second National Health
174 Participants were followed for
vital status through 1998.
175 Vital status through 2003 was obtained from the US Natio
176 5-2003, were followed for their CRC-specific
vital status through 2005 and overall vital status throu
177 ecific vital status through 2005 and overall
vital status through 2006.
178 luated in 1992 to 1996 and were followed for
vital status through 2010.
179 sed by interview shortly after diagnosis and
vital status through 2013 via the National Death Index.
180 lity Linkage Study ascertained participants'
vital status through 2016 with linkage to the National D
181 They compared
vital status through 7 years ascertained from an NDI sea
182 iagnosed between 1988-2009 in California for
vital status through December 31, 2010.
183 quartile range, 43-89 months) (follow-up for
vital status through December 31, 2011), 2119 patients (
184 988 and 2005 in California were observed for
vital status through November 2007.
185 ual characteristics in 1982 and follow-up of
vital status through to 2000.
186 Death Index was used to ascertain patients'
vital statuses through 2007.
187 Death Index was used to ascertain patients'
vital statuses through December 31, 2007.
188 ex and Social Security Death Master File for
vital status to 2016.
189 s, the authors recommend a revised two-stage
vital status tracing protocol.
190 0 (n = 1,137,311) and tracked each subject's
vital status until December 31, 2009.
191 criteria) was assembled and followed up for
vital status until July 1, 2008.
192 Vital status up to 1 year after discharge was obtained f
193 S (SYNTAX Extended Survival) study evaluated
vital status up to 10 years in 1,800 patients with de no
194 NTAX Extended Survival [SYNTAXES]) evaluated
vital status up to 10 years in patients who were origina
195 in cryopreserved serum samples and reviewed
vital status up to Jan 1, 2011, through contact with nex
196 match criteria, further supplemented by CLU
vital status updates, improves vital status assessment w
197 The cohort was actively followed up for
vital status via a trimonthly mobile phone call to each
198 Vital status was ascertained 12-16 y later.
199 Vital status was ascertained by contacting participants
200 Vital status was ascertained by direct subject and famil
201 Vital status was ascertained by telephone and by queryin
202 Long-term
vital status was ascertained by using the respective Nat
203 Vital status was ascertained for 1429 (99.2%) participan
204 Vital status was ascertained for 604 (93.1%), of whom 55
205 between June 10, 2011, and Aug 27, 2012, and
vital status was ascertained for 860 (87%).
206 Median follow-up was 31 months,
vital status was ascertained in 99.6% of patients, and t
207 Vital status was ascertained in a random sample of 208 p
208 Vital status was ascertained on 96.9% of the OOA cohort
209 Vital status was ascertained through 1992.
210 The
vital status was ascertained through computerized linkag
211 ecember 2010 (median follow-up of 20 years),
vital status was ascertained with a National Death Index
212 lost patients were sought, and in 175 (85%)
vital status was ascertained.
213 In addition, the
vital status was assessed at 24 months.
214 Vital status was assessed at 6 months of age.
215 Vital status was assessed over 2 years, and outcomes wer
216 Vital status was assessed through 180 days.
217 Follow-up
vital status was assessed, with the primary endpoint of
218 Vital status was available for 11 621 patients.
219 Vital status was available for 97.2% of patients at 3 ye
220 Vital status was available in more than 95% of participa
221 variables were measured, and information on
vital status was collected from demographic files at fol
222 eexamination (1990-1993), and information on
vital status was collected over the subsequent 5 years.
223 Data on
vital status was collected through December 31, 2014.
224 Vital status was collected.
225 as completed in June 2000, and follow-up for
vital status was completed in September 2007.
226 Vital status was confirmed for >99% of 1,954 patients.
227 Vital status was determined by linkage to the National D
228 Vital status was determined by ongoing contact and a Nat
229 Vital status was determined from hospital records and th
230 Vital status was determined in 1972.
231 Vital status was determined in 361 participants (97.8%)
232 Vital status was determined through December 31, 2011.
233 Vital status was determined using the Social Security De
234 Vital status was established for all but 3 of 1351 patie
235 Vital status was followed for 9 years.
236 Vital status was followed from 1942 to 2003, and cause-s
237 Vital status was followed through December 30, 2003 (med
238 Vital status was followed up to 32.5 years.
239 the United States Renal Data System's data;
vital status was from the National Death Index.
240 ; 49% recent heart failure hospitalization),
vital status was known for 5636 (99.8%).
241 Vital status was known for all men on the 25th anniversa
242 At trial completion,
vital status was not known for 143 (1%) patients who wer
243 Vital status was not known for 2.3% of the patients at 1
244 Vital status was obtained by linkage to the National Dea
245 Vital status was obtained from record linkages with the
246 Vital status was obtained from the Social Security Death
247 By National Death Index,
vital status was obtained in 99.7% (n = 8221) with a mea
248 Infant
vital status was recorded for 28 completed days.
249 After follow-up, the
vital status was recorded in all patients.
250 randomization; at the time of analysis, the
vital status was unknown for 45 patients (0.6%), and thi
251 At the time of our analyses, the
vital status was unknown for 45 patients (0.6%).
252 Vital status was updated telephonically once every 3 mon
253 Vital status was verified in each patient.
254 he national population register to determine
vital status were combined with data from Europe and Nor
255 y status, gestational age, birth weight, and
vital status were measured to estimate the prevalence of
256 Patients'
vital statuses were tracked using the National Death Ind
257 -TB mortality determined by cross-validating
vital status with Georgia's death registry through Novem
258 Vital status within 24 h of the echocardiographic study